Technology | Advanced Visualization | May 11, 2018

EnvoyAI, TeraRecon and Insignia Bringing Artificial Intelligence to U.K. Customers

Integration brings AI-enhanced imaging workflows to Insignia’s InSight PACS and TeraRecon’s iNtuition advanced visualization software

EnvoyAI, TeraRecon and Insignia Bringing Artificial Intelligence to U.K. Customers

May 11, 2018 — EnvoyAI announced a new integration with Insignia Medical Systems’ InSight PACS (picture archiving and communication system) to provide artificial intelligence (AI)-enhanced imaging workflows to customers. For initial launch in the U.K., this integration provides curated AI content available on the EnvoyAI platform within the PACS environment at multiple integration points.  These include AI results viewing directly within the PACS viewer, as well as within the already established Insignia integration with TeraRecon.

The integrations with EnvoyAI and TeraRecon allow hospitals to customize their AI portfolio based on algorithms they can test and consume from within their Insignia PACS, including the utilization of each hospital’s own internally developed algorithms.

The EnvoyAI platform readies the Insignia InSight PACS for the launch of any AI application – starting with the AI content already available on the EnvoyAI Exchange.  With recent growth, the EnvoyAI Exchange now offers a total of 53 products from 22 partners, of which 10 have already achieved U.S. Food and Drug Administration (FDA) clearance. The partnership creates added potential for future workflow integrations to TeraRecon’s iNtuition advanced visualization solution already promoted by Insignia, as well as TeraRecon’s new NorthStar AI-results viewer for advanced physician interactions.

The integration will be displayed in the EnvoyAI and TeraRecon booths at the 2018 Society for Imaging Informatics in Medicine (SIIM) Annual Meeting, May 31-June 2 in National Harbor, Md.

For more information: www.terarecon.com, www.envoyai.com, www.insigniamedical.co.uk

 

Related Content

Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...
LVivo EF Cardiac Tool Now Available for GE Vscan Extend Handheld Mobile Ultrasound
Technology | Cardiovascular Ultrasound | September 19, 2018
DiA Imaging Analysis Ltd. (DiA), a provider of artificial intelligence (AI)-powered ultrasound analysis tools,...
Exact Imaging Partners to Improve Prostate Cancer Detection With Artificial Intelligence
News | Prostate Cancer | September 19, 2018
Exact Imaging, makers of the ExactVu micro-ultrasound platform, has partnered with U.K.-based Cambridge Consultants to...
SimonMed Deploys ClearRead CT Enterprise Wide
News | Computer-Aided Detection Software | September 17, 2018
September 17, 2018 — National outpatient physician radiology group SimonMed Imaging has selected Riverain Technologie
SmartCurve technology, a revolutionary breast imaging technology designed specifically for the curvature of the female breast to provide every woman with a more comfortable and accurate mammogram.
News | Mammography | September 14, 2018
Solis Mammography declared September Breast Wellness Month a
At RSNA 2018, radiology professionals will discover intelligent radiography powered by MUSICA, at Agfa's booth.

At RSNA 2018, radiology professionals will discover intelligent radiography powered by MUSICA, at Agfa's booth.

News | Digital Radiography (DR) | September 13, 2018
At RSNA 2018, radiology professionals will discover intelligent
Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Acuson Sequoia
News | Ultrasound Imaging | September 12, 2018
Siemens Healthineers announced the first global installation of its newest ultrasound system, the...
Lightvision near-infrared fluorescence imaging system
News | Women's Health | September 11, 2018
Shimadzu Corp.